ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.77
-1.09%
US Tech 100
20,778.00
-0.69%
S&P 500
6,040.53
-0.50%
US Dollar vs CAD
1.45415
0.01%
Bitcoin
98,776.40
-1.88%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. ImmunoPrecise Antibodies Ltd (IPA)

  7. ImmunoPrecise Antibodies Ltd (IPA) News

IPA

ImmunoPrecise Antibodies (IPA)

ImmunoPrecise Antibodies Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IPA
DateTimeSourceHeadlineSymbolCompany
01/27/20254:16PMBusiness WireImmunoPrecise Antibodies (IPA) annonce la réalisation d'un placement d'actions sur le marché et la conversion complète de la débenture de YorkvilleNASDAQ:IPAImmunoPrecise Antibodies Ltd
01/27/20259:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
01/27/20257:01AMBusiness WireImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville DebentureNASDAQ:IPAImmunoPrecise Antibodies Ltd
01/24/202512:58PMEdgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:IPAImmunoPrecise Antibodies Ltd
01/22/20251:19PMBusiness WireIPA (ImmunoPrecise Antibodies), pionnier des thérapies GLP-1 conçues par l'IA : Un nouveau chapitre potentiel en matière de traitement du diabèteNASDAQ:IPAImmunoPrecise Antibodies Ltd
01/22/20259:30AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
01/22/20256:02AMBusiness WireIPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes TreatmentNASDAQ:IPAImmunoPrecise Antibodies Ltd
01/17/20258:25PMBusiness WireImmunoPrecise Antibodies redéfinit sa stratégie de pipeline en faisant appel à l'IA et à l'innovation basée sur les principes premiers pour la découverte de médicamentsNASDAQ:IPAImmunoPrecise Antibodies Ltd
01/17/202510:30AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
01/17/20257:01AMBusiness WireImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles InnovationNASDAQ:IPAImmunoPrecise Antibodies Ltd
01/03/20259:20AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
01/01/20256:44AMBusiness WireL'IPA annonce la démission de sa directrice financièreNASDAQ:IPAImmunoPrecise Antibodies Ltd
12/31/20246:56PMBusiness WireIPA Announces Resignation of Chief Financial OfficerNASDAQ:IPAImmunoPrecise Antibodies Ltd
12/23/202411:02AMBusiness WireImmunoPrecise Antibodies (IPA) démontre une solide confiance du marché avec des achats d'actions par des membres de la directionNASDAQ:IPAImmunoPrecise Antibodies Ltd
12/23/20248:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
12/23/20247:30AMBusiness WireImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share PurchasesNASDAQ:IPAImmunoPrecise Antibodies Ltd
12/19/202411:56AMBusiness WirePrésentation de l'IPA à la Microcap Conference 2025NASDAQ:IPAImmunoPrecise Antibodies Ltd
12/19/20247:00AMBusiness WireIPA to Present at The Microcap Conference 2025NASDAQ:IPAImmunoPrecise Antibodies Ltd
12/11/20245:34AMBusiness WireImmunoPrecise Antibodies (IPA) publie ses résultats financiers et les faits saillants de ses activités du deuxième trimestre de l’exercice 2025NASDAQ:IPAImmunoPrecise Antibodies Ltd
12/10/20247:37AMEdgar (US Regulatory)Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]NASDAQ:IPAImmunoPrecise Antibodies Ltd
12/10/20247:36AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
12/10/20247:33AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
12/10/20247:30AMBusiness WireImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025NASDAQ:IPAImmunoPrecise Antibodies Ltd
12/05/20245:23AMBusiness WireL'IPA participera à la prochaine conférence de découverte en tête-à-tête d'investisseurs organisée par The Benchmark CompanyNASDAQ:IPAImmunoPrecise Antibodies Ltd
12/04/20247:00AMBusiness WireIPA to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor ConferenceNASDAQ:IPAImmunoPrecise Antibodies Ltd
12/03/202410:08PMBusiness WireL'IPA publiera ses résultats financiers et les faits importants de son activité récente pour le deuxième trimestre de l'exercice 2025 le 10 décembre 2024NASDAQ:IPAImmunoPrecise Antibodies Ltd
12/03/20247:33AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
12/03/20247:30AMBusiness WireIPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024NASDAQ:IPAImmunoPrecise Antibodies Ltd
11/14/20242:13PMBusiness WireUne percée commerciale de 20 milliards de dollars : l'IPA est pionnière dans le développement d'anticorps à fort impact pour les thérapies anticancéreuses ADC de nouvelle générationNASDAQ:IPAImmunoPrecise Antibodies Ltd
11/13/20248:17AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
 Showing the most relevant articles for your search:NASDAQ:IPA

Your Recent History

COIN
XRPUSD
Ripple
USOTC
NWBO
Northwest Biotherapeutics (QB)
USOTC
BIEL
Bioelectronics (PK)
NASDAQ
LWLG
Lightwave Logic
USOTC
RDGL
Vivos (QB)
USOTC
NBRI
North Bay Resources (PK)
NASDAQ
COOP
Mr Cooper
NASDAQ
NVDA
NVIDIA
NASDAQ
AMRN
Amarin
USOTC
FNMA
Fannie Mae (QB)
USOTC
ELTP
Elite Pharmaceuticals (QB)
NASDAQ
AVXL
Anavex Life Sciences
USOTC
HMBL
HUMBL (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads